Asian Journal of Pharmaceutical Research and Health Care

Open Access Open Access  Restricted Access Subscription Access

Prediction of In-vivo Performance of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets using Biorelevant Dissolution Tests


Affiliations
1 Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram − 608002, Tamil Nadu, India
2 Malla Reddy Pharmacy College, Maisammaguda, Hyderabad − 500014, India
 

Main objective of this research work was to develop a biorelevant dissolution method by correlating the in-vivo behavior of Naproxen and Esomeprazole magnesium delayed release tablets 500/20mg, when administered orally under pre-prandial condition. The target dissolution profile for bio-relevant dissolution media was derived, by deconvoluting mean blood plasma concentration time profile of Naproxen and Esomeprazole, achieved after oral administration under pre-prandial condition. The dissolution media volume and RPM were optimized using full factorial design of experiment. The dissolution profile observed with office of generic drugs recommended dissolution media was faster in release for Naproxen part and slower in release for Esomeprazole part in comparison to target release of bio-relevant dissolution method, with the F2 value of 31 for Naproxen and 29 for Esomeprazole. USP Apparatus-I with fasted state simulated gastro intestinal change over dissolution media were used for method development. Based on ANOVA results, for Naproxen part, 250ml of fasting change over dissolution medium, and 50RPM, with the desirability factor of 0.508 was concluded as bio relevant dissolution medium. For esomeprazole part, the 900ml of fasting change over dissolution medium, and 100RPM, with the desirability factor of 0.479 was concluded as bio-relevant dissolution medium. The F2 value observed between in-vitro and in-vivo dissolution profile is 64 and 63, the regression co-efficient (R2) value of 0.987 and 0.997 for Naproxen and Esomeprazole respectively demonstrates a very good in-vitro/in-vivo correlation under pre-prandial condition. The developed method shall be used as a predictive in-vitro tool for evaluation Naproxen from Naproxen and Esomeprazole magnesium delayed release tablets, and also gives the advantage for claiming bio-waiver for remaining strengths.


Keywords

Bio-Relevant, Delayed Release, Esomeprazole, Magnesium, Naproxen, Pre-Prandial.
User
Notifications
Font Size

  • US Food and Drug Administration, Silver Spring, MD 20993, Center for Drug Evaluation and Research, 2010, Printed Labeling for Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets 30th April 2010. Cited 2018 April 5. https://www.accessdata.fda.gov/drugsatfda_ docs/nda/2010/022511Orig1s000Lbl.pdf.

  • Gaurav Gujral, Devesh Kapoor, Manish Jaimini. An updated review on modified release tablets. Journal of Drug Delivery and Therapeutics. 2018; 8(4):5-9. https:// doi.org/10.22270/jddt.v8i4.1722.

  • Heyam Saad Ali, Rasha Saad Suliman, Babiker MA Elhaj, Raina Suliman, The effect of modified release dosage forms on absorption of medications. International Journal of Pharmaceutical and Clinical Research. 2019; 11(1): 30-33.

  • Bhagat Nitin B, Yadav Adhikrao V, Mali Sachin S, Khutale Rohan A, Hajare Ashok A, Salunkhe Sachin S, Nadaf Sameer J. A review on development of biorelevant dissolution medium. Journal of Drug Delivery and Therapeutics. 2014; 4(2):140-48. https://doi.org/10.22270/jddt.v4i2.800.

  • Bhavyasri K, Murali Balaram V, Nageswarao R, Rambabu D, Ajitha M. Rapid simultaneous determination of naproxen and esomeprazole magnesium in combined tablets by validated ultra performance liquid chromatographic method. Journal of Chemical and Pharmaceutical Research. 2013; 5(12):1230-36.

  • Palavai Sripal Reddy, Shakil Sait, Vasudevmurthy G, Vishwanath B, Prasad V, Jayapal Reddy S. Stability indicating simultaneous estimation of assay method for naproxen and esomeprazole in pharmaceutical formulations by RP-HPLC. Scholars Research Library Der Pharma Chemica. 2011; 3(6):553-64.

  • Jain DK, Jain N, Charde R. The RP-HPLC method for simultaneous estimation of Esomeprazole and Naproxen in binary combination. Pharmaceutical Methods. 2011; 2(3):167-72. https://doi.org/10.4103/2229-4708.90356. PMid: 23781450, PMCid: PMC3658060.

  • Khawla Rashee, Wagner-Nelson and Numerical Deconvolution based approaches for In-Vivo performance prediction. International Journal of Science and Research (IJSR). 2018; 7(8):1646-49.

  • https://pdfs.semanticscholar.org/a8e8/63e064d9395e0 d71ddea9632e45271474e0b.pdf.

  • US Food and Drug Administration, Silver Spring, MD 20993, Center for Drug Evaluation and Research, 2010, Clinical Pharmacology and Biopharmaceutics Review(S), for Vimovo (naproxen/esomeprazole magnesium) delayed release tablets 30th April 2010. Cited 5 April 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/02251 1Orig1s000ClinPharmR.pdf.

  • Andreas CJ, Chen YC, Markopoulos C, Reppas C, Dressman J. In-vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. Eur. J. Pharm. Biopharm., 2015; 97(Pt A): 39-50. https://doi.org/10.1016/j.ejpb.2015.09.002.

  • PMid: 26391972.

  • Jantratid E, Janssen N. Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update. Pharm Res. 2008; 25(7):1663-76. https://doi.org/10.1007/s11095-008-9569-4. PMid: 18404251.

  • Sandra Klein. The use of Biorelevant dissolution media to forecast the In-Vivo performance of a drug. American Association of Pharmaceutical Scientists. 2010; 12(3):397406. https://doi.org/10.1208/s12248-010-9203-3. PMid: 20458565, PMCid: PMC2895438.

  • Ramalingam Peraman, Kalva Bhadraya, Yiragamreddy Padmanabha Reddy, Analytical quality by design: A tool for regulatory flexibility and robust analytics. International Journal of Analytical Chemistry. 2015; 1-9. https://doi.org/10.1155/2015/868727. PMid: 25722723, PMCid: PMC4332986.

  • FDA. Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in Vitro/In-vivo Correlations. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER); 1997. https://www.fda.gov/downloads/drugs/guidances/ucm070239.pdf.

  • Suarez-Sharp S, Li M, Duan J, Shah H, Seo P. Regulatory experience with In-Vivo In-Vitro Correlations (IVIVC) in new drug applications. American Association of Pharmaceutical Scientists. 2016; 18(6):1379-90. https://doi.org/10.1208/s12248-016-9966-2. PMid: 27480319.


Abstract Views: 431

PDF Views: 149




  • Prediction of In-vivo Performance of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets using Biorelevant Dissolution Tests

Abstract Views: 431  |  PDF Views: 149

Authors

Devi Thamizhanban
Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram − 608002, Tamil Nadu, India
Gampa Tulja Rani
Malla Reddy Pharmacy College, Maisammaguda, Hyderabad − 500014, India
Kathiresan Krishnasamy
Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram − 608002, Tamil Nadu, India

Abstract


Main objective of this research work was to develop a biorelevant dissolution method by correlating the in-vivo behavior of Naproxen and Esomeprazole magnesium delayed release tablets 500/20mg, when administered orally under pre-prandial condition. The target dissolution profile for bio-relevant dissolution media was derived, by deconvoluting mean blood plasma concentration time profile of Naproxen and Esomeprazole, achieved after oral administration under pre-prandial condition. The dissolution media volume and RPM were optimized using full factorial design of experiment. The dissolution profile observed with office of generic drugs recommended dissolution media was faster in release for Naproxen part and slower in release for Esomeprazole part in comparison to target release of bio-relevant dissolution method, with the F2 value of 31 for Naproxen and 29 for Esomeprazole. USP Apparatus-I with fasted state simulated gastro intestinal change over dissolution media were used for method development. Based on ANOVA results, for Naproxen part, 250ml of fasting change over dissolution medium, and 50RPM, with the desirability factor of 0.508 was concluded as bio relevant dissolution medium. For esomeprazole part, the 900ml of fasting change over dissolution medium, and 100RPM, with the desirability factor of 0.479 was concluded as bio-relevant dissolution medium. The F2 value observed between in-vitro and in-vivo dissolution profile is 64 and 63, the regression co-efficient (R2) value of 0.987 and 0.997 for Naproxen and Esomeprazole respectively demonstrates a very good in-vitro/in-vivo correlation under pre-prandial condition. The developed method shall be used as a predictive in-vitro tool for evaluation Naproxen from Naproxen and Esomeprazole magnesium delayed release tablets, and also gives the advantage for claiming bio-waiver for remaining strengths.


Keywords


Bio-Relevant, Delayed Release, Esomeprazole, Magnesium, Naproxen, Pre-Prandial.

References





DOI: https://doi.org/10.18311/ajprhc%2F2020%2F25237